Inulin and Protein Fermentation in Hemodialysis Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
An important group of protein-bound uremic retention solutes originate from protein fermentation in the colon. P-cresol is a putrefaction metabolite of tyrosine. Indole is generated by fermentation of tryptophan. After absorption, the majority of p-cresol and indole are further metabolised and conjugated to form p-cresylsulphate and indoxyl sulphate. There is clear evidence, both in vitro and in vivo, that accumulation of these conjugated fermentation metabolites in kidney disease is correlated with clinical (cardiovascular) endpoints.
Bacterial protein fermentation can be influenced by altering the colonic microenvironment, influencing the ratio of available carbohydrates to nitrogen, by shortening the colonic transit time or a combination of these. From a theoretical point of view, functional foods, i.e. pro-, pre- and synbiotics, fulfil these criteria.
Prebiotics have been defined as non-digestible food ingredients that beneficially affect the host by selectively stimulating growth, and/or activity, of one or a restricted number of bacteria in the colon. Dietary fibre may suppress the generation of bacterial protein fermentation either by altering the colonic microenvironment or by shortening the colonic transit time. Animal and clinical studies evaluating the effect of dietary fibre supplements on the generation of bacterial fermentation metabolites have provided conflicting results. These discrepancies may be related to specific properties of the dietary fibre investigated. Dietary fibre may impair protein assimilation and the fermentability may vary to a substantial extent.
Inulin and oligofructose have attracted much attention recently as nonabsorbable carbohydrates with prebiotic properties. When inulin and oligofructose were added to a controlled diet, significant increases were noted in colonic bifidobacterial populations, and it has been proposed that these changes promote both colonic and systemic health through modification of the intestinal microflora. Inulin and oligofructose are rapidly and completely fermented by the colonic microflora with the production of acetate and other short-chain fatty acids. In healthy individuals, supplementation with a mixture of inulin and oligofructose was shown to lower p-cresol generation. Although data in healthy volunteers are promising, no data are available in hemodialysis patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Kidney Disease |
Dietary Supplement: BENEO synergy1 |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase 1/2 Study on the Effects of BENEO synergy1 on the Generation Rate and Serum Concentration of P-cresol and Related Protein-fermentation Endproducts in Haemodialysis Patients |
- Decrease p-cresol serum concentration [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
- Decreased generation rate of p-cresol [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
- Decreased serum concentration of related uremic retention solutes [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
- Change in bowel habits as measured by validated constipation scores [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
- inflammation (c-reactive protein) [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 22 |
| Study Start Date: | March 2006 |
| Study Completion Date: | July 2008 |
| Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: I
BENEO synergy1
|
Dietary Supplement: BENEO synergy1
50/50 v/v inulin/oligofructose 10 gram BID
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Chronic hemodialysis patients on maintenance dialysis treatment.
- 18 years of age or older
- Written informed consent
Exclusion Criteria:
- Use of pre-/pro-/syn- or antibiotics in preceding 4 weeks.
Contacts and Locations| Belgium | |
| Universitaire Ziekenhuizen Leuven | |
| Leuven, Vlaams-Brabant, Belgium, 3000 | |
| Principal Investigator: | Pieter Evenepoel, MD, PhD | University Hospitals Leuven |
| Principal Investigator: | Bjorn Meijers, MD | University Hospitals Leuven |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Björn Meijers, Dr., Universitaire Ziekenhuizen Leuven |
| ClinicalTrials.gov Identifier: | NCT00695513 History of Changes |
| Other Study ID Numbers: | ML3534 |
| Study First Received: | June 10, 2008 |
| Last Updated: | September 14, 2011 |
| Health Authority: | Belgium: Institutional Review Board |
Keywords provided by Universitaire Ziekenhuizen Leuven:
|
Food supplement Haemodialysis |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency, Chronic Kidney Failure, Chronic Urologic Diseases Renal Insufficiency |
ClinicalTrials.gov processed this record on June 17, 2013